司库奇尤单抗治疗巨细胞动脉炎患者的疗效与安全性(TitAIN):一项随机、双盲、安慰剂对照的2期试验
这项在德国11家诊所或医院开展的贝叶斯随机、平行组、双盲、安慰剂对照、多中心2期研究纳入52例新发或复发性巨细胞动脉炎患者,随机接受司库奇尤单抗300mg或安慰剂皮下注射,同时泼尼松龙在26周内逐渐减至0mg。至第28周持续缓解的中位比例司库奇尤单抗组为70%(95%可信区间52-85),安慰剂组为20%(12-30)。两组不良事件发生率相似,司库奇尤单抗耐受性良好,无新的安全性问题。
要点
- 至第28周持续缓解的中位比例司库奇尤单抗组为70%(95%可信区间52-85),安慰剂组为20%(12-30)。
- 司库奇尤单抗组27例中27例(100%)发生任何不良事件,安慰剂组25例中24例(96%)发生任何不良事件。
- 两组各1例患者在研究期间死亡,均被认为与研究治疗无关。
核心结论
- 活动性巨细胞动脉炎患者在接受糖皮质激素逐渐减量方案的基础上,司库奇尤单抗组第28周持续缓解率高于安慰剂组。
- 司库奇尤单抗耐受性良好,无新的安全性问题。
- 这项概念验证性2期研究进一步支持将司库奇尤单抗开发为巨细胞动脉炎患者的治疗选择。
研究设计与样本
- 贝叶斯随机、平行组、双盲、安慰剂对照、多中心2期研究,在德国11家诊所或医院开展。
- 纳入年龄50岁及以上、新发或复发性巨细胞动脉炎、未接受过生物制剂治疗且已使用泼尼松龙等效剂量25-60 mg/天的患者。
- 52例患者按1:1随机分配至司库奇尤单抗300 mg组(n=27)或安慰剂组(n=25),皮下注射每周一次至第4周,此后每4周一次。
- 两组泼尼松龙剂量均在26周内逐渐减至0 mg。
- 主要终点为至第28周持续缓解患者的中位比例(贝叶斯分析),在意向治疗分析集(即所有接受至少一剂指定治疗、按随机分组分析的患者)中评估。
主要发现
- 52例入组患者中位年龄75岁(IQR 69-79),女性35例(67%)、男性17例(33%),52例(100%)为白人。
- 司库奇尤单抗组27例中4例、安慰剂组25例中8例在第28周前停止治疗。
- 基于贝叶斯分析,至第28周持续缓解的中位比例司库奇尤单抗组为70%(95%可信区间52-85),安慰剂组为20%(12-30)。
- 任何不良事件发生率司库奇尤单抗组为27例中27例(100%),安慰剂组为25例中24例(96%)。
- 最常见不良事件为高血压(司库奇尤单抗组27例中6例[22%],安慰剂组25例中8例[32%])和鼻咽炎(司库奇尤单抗组27例中5例[19%],安慰剂组25例中5例[20%])。
关键数值与推荐
- 主要终点:至第28周持续缓解的中位比例司库奇尤单抗组70%(95%可信区间52-85)vs 安慰剂组20%(12-30)。
- 安全性分析集(即所有接受至少一剂研究治疗、按实际接受治疗分析的患者)中,任何不良事件司库奇尤单抗组27例中27例(100%)vs 安慰剂组25例中24例(96%)。
- 高血压:司库奇尤单抗组27例中6例(22%)vs 安慰剂组25例中8例(32%)。
- 鼻咽炎:司库奇尤单抗组27例中5例(19%)vs 安慰剂组25例中5例(20%)。
- 研究期间死亡2例(每组各1例),均被认为与研究治疗无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The treatment of giant cell arteritis with glucocorticoid-sparing agents is an unmet medical need. We evaluated the efficacy and safety of secukinumab, an anti-interleukin-17A monoclonal antibody, in patients with giant cell arteritis. METHODS: We conducted a Bayesian randomised, parallel-group, double-blind, placebo-controlled, multicentre, phase 2 study at 11 clinics or hospitals in Germany. Patients aged 50 years or older with new-onset or relapsing giant cell arteritis who were naive to biological therapy and already receiving glucocorticoids with a prednisolone equivalent dose of 25-60 mg/day were eligible for inclusion. Participants were assigned (1:1) to receive 300 mg secukinumab or placebo subcutaneously once a week up to week 4 and every 4 weeks thereafter. In both treatment groups, prednisolone dose was tapered down to 0 mg over a 26-week period. Patients, investigator staff, and clinical trial team were masked to the treatment assignment. The primary endpoint was the median proportion (Bayesian analysis) of patients with sustained remission until week 28 in the full analysis set (ie, all patients who received at least one dose of assigned treatment, analysed according to treatment assigned at randomisation). Sustained remission rate of the placebo group from a previous trial of tocilizumab in patients with giant cell arteritis was used to derive the prior distribution of placebo sustained remission rate for the primary endpoint. The safety of secukinumab was assessed in the safety set (ie, all patients who received at least one dose of study treatment, analysed according to study treatment received). This trial is completed and is registered with ClinicalTrials.gov, NCT03765788. FINDINGS: Of the 65 patients who were assessed for eligibility, 52 patients (median age 75 years [IQR 69-79]; 35 [67%] female and 17 [33%] male, 52 [100%] White) were enrolled between Jan 30, 2019 and March 30, 2020 and were randomly assigned to receive secukinumab (n=27) or placebo (n=25). Four of 27 patients in the secukinumab group and eight of 25 patients in the placebo group discontinued treatment by week 28 of the study. On the basis of the Bayesian analysis, the median proportion of patients in sustained remission until week 28 was 70% (95% credibility interval 52-85) in the secukinumab group versus 20% (12-30) in the placebo group. The incidence of adverse events was similar in the secukinumab (27 [100%] of 27 patients had any adverse event) and placebo groups (24 [96%] of 25 patients had any adverse event); the most common adverse events were hypertension (six [22%] of 27 patients in the secukinumab group and eight [32%] of 25 patients in the placebo group) and nasopharyngitis (five [19%] of 27 patients in the secukinumab group and five [20%] of 25 patients in the placebo group). Two patients (one in each group) died during the study, neither of which was considered to be related to study treatment. INTERPRETATION: Patients with active giant cell arteritis had a higher sustained remission rate in the secukinumab group than in the placebo group at week 28, in combination with glucocorticoid taper regimen. Secukinumab was tolerated well with no new safety concerns. This proof-of-concept phase 2 study further supports the development of secukinumab as a treatment option for people with giant cell arteritis. FUNDING: Novartis Pharma.
引用
- Venhoff N, Schmidt WA, Bergner R, et al. Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Rheumatol. 2023. PMID: 38251601. doi:10.1016/S2665-9913(23)00101-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。